Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL502252 | 0.97 | HTT (0.42) | HTTSMN1; SMN2LMNAPOLBAPOBEC3G | |
| SCHEMBL29560985 | 0.87 | SMN1; SMN2 (0.44) | HTTSMN1; SMN2LMNAPOLBAPOBEC3G | |
| SCHEMBL4501039 | 0.87 | SMN1; SMN2 (0.44) | HTTSMN1; SMN2LMNAPOLBAPOBEC3G | |
| SCHEMBL16346063 | 0.84 | NOS2 (0.52) | HTTSMN1; SMN2NOS3NOS1NOS2 | |
| SCHEMBL501313 | 0.84 | HTT (0.37) | HTTSMN1; SMN2LMNAPOLBAPOBEC3G | |
| SCHEMBL23458233 | 0.80 | HTT (0.42) | HTTSMN1; SMN2LMNAKMT2AMEN1 | |
| SCHEMBL9494083 | 0.79 | HTT (0.36) | HTTSMN1; SMN2LMNAPOLBAPOBEC3G | |
| SCHEMBL377724 | 0.78 | ACHE (0.43) | HTTLMNAPOLBAPOBEC3GKMT2A | |
| SCHEMBL10144468 | 0.77 | LMNA (0.40) | HTTLMNAPOLBAPOBEC3GNOS3 | |
| SCHEMBL13008173 | 0.77 | LMNA (0.40) | HTTLMNAPOLBAPOBEC3GKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3704094-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250122188-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2025-04-17 | — | — | US | disclosed |
| US-20240166652-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-05-23 | — | — | US | disclosed |
| EP-4356971-A2 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2024-04-24 | — | — | EP | disclosed |
| CN-115947681-A | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2023-04-11 | — | — | CN | disclosed |
| US-20220363678-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2022-11-17 | — | — | US | disclosed |
| CN-109641844-B | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2022-11-01 | — | — | CN | disclosed |
| US-20210300943-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-30 | — | — | US | disclosed |
| US-20210277015-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN-CILAG S.A. (ES) | 2021-09-09 | — | — | US | disclosed |
| WO-2021110656-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-10 | — | — | WO | disclosed |
| US-5001138-A | Insecticides | NIHON TOKUSHU NOYAKU SEIZO, K.K. (JP) | 1991-03-19 | — | — | US | disclosed |
| US-4845106-A | INSECTICIDES | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1989-07-04 | — | — | US | disclosed |
| US-4812571-A | NITROMETHYLENE COMPOUNDS | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1989-03-14 | — | — | US | disclosed |
| CN-1031079-A | Alpha-unsaturated amines, process for their production and their use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1989-02-15 | — | — | CN | disclosed |
| EP-0302389-A2 | Alpha-unsaturated amines, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1989-02-08 | — | — | EP | disclosed |
| US-4774247-A | Nitromethylene derivative insecticides | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1988-09-27 | — | — | US | disclosed |
| US-4742060-A | 2-(NITROIMINO)- OR 2-(NITROMETHYLENE)-IMIDAZOLIDINES AS INSECTICIDES | NIHON TOKUSHU NOYAKU SEIZO K. K. (JP) | 1988-05-03 | — | — | US | disclosed |
| US-4678795-A | 1-pyridylmethyl-2-nitromethylene-1,3-diazacycloalkane insecticides | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1987-07-07 | — | — | US | disclosed |
| EP-0192060-A1 | Heterocyclic compounds | NIHON BAYER AGROCHEM K.K. (JP) | 1986-08-27 | — | — | EP | disclosed |
| EP-0163855-A1 | Nitromethylene derivatives, intermediates, and process for their preparation as insecticides | NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) | 1985-12-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122188-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | HTT 2496/4885SMN1; SMN2 2486/4885LMNA 3376/4885 |
| US-20210300943-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | HTT 33/4885SMN1; SMN2 103/4885LMNA 848/4885 |
| US-20210277015-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | HTT 33/4885SMN1; SMN2 103/4885LMNA 848/4885 |
| US-20240166652-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | HTT 2496/4885SMN1; SMN2 2486/4885LMNA 3376/4885 |
| US-20220363678-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | HTT 2496/4885SMN1; SMN2 2486/4885LMNA 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.